4.0 Article

Cardiovascular Risk Prediction in Diabetic Men and Women Using Hemoglobin A1c vs Diabetes as a High-Risk Equivalent

Journal

ARCHIVES OF INTERNAL MEDICINE
Volume 171, Issue 19, Pages 1712-1718

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/archinternmed.2011.351

Keywords

-

Funding

  1. F. Hoffmann-La Roche, Ltd.
  2. Leducq Foundation
  3. Roche Diagnostics
  4. Amgen, Inc
  5. AstraZeneca
  6. Novartis
  7. Merck
  8. Abbott
  9. sanofi-aventis
  10. Schering-Plough
  11. Isis
  12. Siemens
  13. Vascular Biogenics
  14. National Heart Lung and Blood Institute [HL 043851, HL 080467, CA 047988, CA 97193, CA 34944, CA 40360, HL 26490, HL 34595]
  15. National Cancer Institute, Bethesda, Maryland
  16. Donald W. Reynolds Foundation, Las Vegas, Nevada

Ask authors/readers for more resources

Background: It is unclear whether models that include hemoglobin A(1c) (HbA(1c)) levels only for diabetic patients improve the ability to predict cardiovascular disease (CVD) risk compared with the currently recommended classification of diabetes as a cardiovascular risk equivalent. Methods: A total of 24 674 women (including 685 diabetic participants at baseline) and 11 280 men (including 563 diabetic participants at baseline) were followed up prospectively for cardiovascular disease (CVD). One hundred twenty-five CVD events occurred in diabetic women (666 in nondiabetic women), and 170 events occurred in diabetic men (1382 in nondiabetic men). Models for CVD risk were generated separately for men and women using the traditional CVD risk factors with the addition of a term for HbA(1c) levels only for diabetic individuals. In diabetic participants, the resulting predicted risks were compared with classification of diabetes as a cardiovascular risk equivalent (10-year CVD risk of at least 20%). Results: In women, the models including HbA(1c) levels in diabetic participants improved the C statistic by 0.177 (P < .001) over the risk equivalence model and showed improved reclassification (net reclassification improvement [NRI] of 26.7% [P = .001]). In men, the improvements were more modest but still statistically significant (C statistic change of 0.039 [P = .02]; NRI of 9.2% [P = .04]). Including HbA1c levels also improved prediction over a dichotomous term for diabetes in women (NRI of 11.8% [P = .03]) but not in men. Conclusions: In both women and men with diabetes at baseline, we observed significant improvements in predictive ability of CVD risk using models incorporating HbA(1c) levels compared with classification of diabetes as a cardiovascular risk equivalent.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available